This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cabaletta Bio’s 8K filing here.
Cabaletta Bio Company Profile
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
Recommended Stories
- Five stocks we like better than Cabaletta Bio
- Top Biotech Stocks: Exploring Innovation Opportunities
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Best Stocks Under $10.00
- Applied Materials Market Capitulates: Now is the Time to Buy
- Investing In Preferred Stock vs. Common Stock
- 3 Ultra-High Dividend Yield Stocks for the New Year
